Andy Emba

Andy Emba is the Global Program Head for the early portfolio in cardiovascular, renal, and metabolism at Novartis. He is also the founder and President of OoNiDa, a not-for-profit association focusing on citizen-centric health ecosystems. With a background in the Pharmaceutical Industry, Andy has extensive experience in discovery, development, marketing, sales, M&A, business innovation, and corporate social responsibility.

Andy Emba's leadership roles have spanned across Oncology, Migraine, Cardiovascular Disease, Metabolism, and Diabetes within the pharmaceutical sector. He has overseen large departments such as Project Management in Pharma and R&D Operations in OTC. Andy is known for his visionary leadership, integrity, and motivation skills that empower diverse teams to achieve remarkable success.

Having completed his Executive MBA at INSEAD in 2017, Andy Emba aims to significantly impact health system efficiency. He is a creative and innovative individual who excels in building businesses and driving bold visionary strategies alongside fellow executives. Andy also has a passion for coaching and witnessing the growth of his colleagues, earning recognition like the 'Best and Brightest EMBA 2017' award from INSEAD.

Education-wise, Andy Emba holds a Global Executive MBA from INSEAD, a BSc, and a PhD in Chemistry from The University of Sheffield, and a Diploma in Spanish as a Foreign Language from Universidad Autónoma de Madrid.

In his professional journey, Andy Emba has been associated with reputable organizations such as Novartis and OoNiDa in various capacities including Global Program Head, CEO, Co-President, and Head of Global R&D Operations and Innovation. He has also held positions at Pfizer in Full Development Project Management.